Skip to Main Content


On June 27, 2024, Elanco issued a press release providing updates to the company’s expected FDA approval timelines for its animal disease treatments, Zenrelia and Credelio Quattro. In the release, Elanco stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024, despite the company having previously set a launch timeline for the third quarter of 2024. Elanco also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, despite having previously set an approval timeline for the third quarter of 2024. 

On this news, Elanco's stock price fell $3.69 per share, or 20.53%, to close at $14.28 per share on June 27, 2024.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at  

Complete this form with your transactions in Elanco Animal Health Incorporated
 securities between November 29, 2023 and June 26, 2024.

Click Here to Print PDF of this Form

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Elanco Animal Health Incorporated prior to the Class Period?
Are you a current or former employee of Elanco Animal Health Incorporated?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email